Michael Holinstat

List of Publications by Year
in descending order

107 papers	4,111 citations	94433 37 h-index	118850 62 g-index
110 all docs	110 docs citations	110 times ranked	5260 citing authors

#	Article	IF	Citations
1	Normal platelet function. Cancer and Metastasis Reviews, 2017, 36, 195-198.	5.9	242
2	Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood, 2014, 123, e37-e45.	1.4	199
3	RhoA Interaction with Inositol 1,4,5-Trisphosphate Receptor and Transient Receptor Potential Channel-1 Regulates Ca2+ Entry. Journal of Biological Chemistry, 2003, 278, 33492-33500.	3.4	198
4	Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nature Medicine, 2013, 19, 1609-1616.	30.7	190
5	Functional Selectivity of G Protein Signaling by Agonist Peptides and Thrombin for the Protease-activated Receptor-1. Journal of Biological Chemistry, 2005, 280, 25048-25059.	3.4	173
6	Protein Kinase CÎ± Phosphorylates the TRPC1 Channel and Regulates Store-operated Ca2+ Entry in Endothelial Cells. Journal of Biological Chemistry, 2004, 279, 20941-20949.	3.4	160
7	Suppression of RhoA Activity by Focal Adhesion Kinase-induced Activation of p190RhoGAP. Journal of Biological Chemistry, 2006, 281, 2296-2305.	3.4	150
8	Protein Kinase CÎ±-Induced p115RhoGEF Phosphorylation Signals Endothelial Cytoskeletal Rearrangement. Journal of Biological Chemistry, 2003, 278, 28793-28798.	3.4	141
9	Anti-inflammatory Ï‰-3 endocannabinoid epoxides. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6034-E6043.	7.1	136
10	Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases. Pharmacological Reviews, 2018, 70, 526-548.	16.0	131
11	Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood, 2014, 124, 3450-3458.	1.4	107
12	PAR4, but Not PAR1, Signals Human Platelet Aggregation via Ca2+ Mobilization and Synergistic P2Y12 Receptor Activation. Journal of Biological Chemistry, 2006, 281, 26665-26674.	3.4	99
13	Modulatory role of focal adhesion kinase in regulating human pulmonary arterial endothelial barrier function. Journal of Physiology, 2002, 539, 779-789.	2.9	83
14	Platelet 12-LOX is essential for FcÎ³RIIa-mediated platelet activation. Blood, 2014, 124, 2271-2279.	1.4	81
15	Investigations of human platelet-type 12-lipoxygenase: role of lipoxygenase products in platelet activation. Journal of Lipid Research, 2012, 53, 2546-2559.	4.2	77
16	MicroRNA Expression Differences in Human Hematopoietic Cell Lineages Enable Regulated Transgene Expression. PLoS ONE, 2014, 9, e102259.	2.5	77
17	First Selective 12-LOX Inhibitor, ML355, Impairs Thrombus Formation and Vessel Occlusion In Vivo With Minimal Effects on Hemostasis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1828-1839.	2.4	76
18	PAR1, but Not PAR4, Activates Human Platelets through a Gi/o/Phosphoinositide-3 Kinase Signaling Axis. Molecular Pharmacology, 2007, 71, 1399-1406.	2.3	73

#	Article	IF	Citations
19	The emerging role of oxylipins in thrombosis and diabetes. Frontiers in Pharmacology, 2014, 4, 176.	3.5	73
20	Regulation of platelet function and thrombosis by omega-3 and omega-6 polyunsaturated fatty acids. Prostaglandins and Other Lipid Mediators, 2018, 139, 10-18.	1.9	72
21	Neutrophilâ€“Particle Interactions in Blood Circulation Drive Particle Clearance and Alter Neutrophil Responses in Acute Inflammation. ACS Nano, 2017, 11, 10797-10807.	14.6	71
22	The expansive role of oxylipins on platelet biology. Journal of Molecular Medicine, 2017, 95, 575-588.	3.9	70
23	Synthesis and Structureâ€“Activity Relationship Studies of 4-((2-Hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives as Potent and Selective Inhibitors of 12-Lipoxygenase. Journal of Medicinal Chemistry, 2014, 57, 495-506.	6.4	67
24	Interaural Level Difference Processing in the Lateral Superior Olive and the Inferior Colliculus. Journal of Neurophysiology, 2004, 92, 289-301.	1.8	61
25	GPR56/ADGRG1 is a platelet collagen-responsive GPCR and hemostatic sensor of shear force. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28275-28286.	7.1	61
26	Rap1-Rac1 Circuits Potentiate Platelet Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 434-441.	2.4	60
27	12(S)-HETrE, a 12-Lipoxygenase Oxylipin of Dihomo-Î³-Linolenic Acid, Inhibits Thrombosis via GÎ± _s Signaling in Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2068-2077.	2.4	60
28	Discovery of Potent and Selective Inhibitors of Human Platelet-Type 12- Lipoxygenase. Journal of Medicinal Chemistry, 2011, 54, 5485-5497.	6.4	59
29	12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2011, 9, 154-164.	1.0	59
30	Protease-Activated Receptor Signaling in Platelets Activates Cytosolic Phospholipase A _{2Î±} Differently for Cyclooxygenase-1 and 12-Lipoxygenase Catalysis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 435-442.	2.4	56
31	12-lipoxygenase activity plays an important role in PAR4 and GPVI-mediated platelet reactivity. Thrombosis and Haemostasis, 2013, 110, 569-581.	3.4	54
32	Mechanism of Race-Dependent Platelet Activation Through the Protease-Activated Receptor-4 and Gq Signaling Axis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2644-2650.	2.4	50
33	Exploring deformable particles in vascular-targeted drug delivery: Softer is only sometimes better. Biomaterials, 2017, 124, 169-179.	11.4	45
34	Targeting 12-Lipoxygenase as a Potential Novel Antiplatelet Therapy. Trends in Pharmacological Sciences, 2017, 38, 1006-1015.	8.7	45
35	Newer agents in antiplatelet therapy: a review. Journal of Blood Medicine, 2012, 3, 33.	1.7	42
36	Protein Kinase C Regulation of 12-Lipoxygenase-Mediated Human Platelet Activation. Molecular Pharmacology, 2012, 81, 420-430.	2.3	38

#	Article	IF	Citations
37	Protease-Activated Receptors Differentially Regulate Human Platelet Activation through a Phosphatidic Acid-Dependent Pathway. Molecular Pharmacology, 2007, 71, 686-694.	2.3	37
38	15-Lipoxygenase-1 biosynthesis of 7S,14S-diHDHA implicates 15-lipoxygenase-2 in biosynthesis of resolvin D5. Journal of Lipid Research, 2020, 61, 1087-1103.	4.2	35
39	Role of protein kinase CÎ¶ in thrombin-induced RhoA activation and inter-endothelial gap formation of human dermal microvessel endothelial cell monolayers. Microvascular Research, 2010, 80, 240-249.	2.5	34
40	Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1632-1643.	2.4	31
41	Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19. European Journal of Pharmacology, 2021, 898, 173988.	3.5	31
42	Deformable microparticles for shuttling nanoparticles to the vascular wall. Science Advances, 2021, 7, .	10.3	28
43	Irreversible Platelet Activation Requires Protease-Activated Receptor 1-Mediated Signaling to Phosphatidylinositol Phosphates. Molecular Pharmacology, 2009, 76, 301-313.	2.3	27
44	12-HETrE inhibits platelet reactivity and thrombosis in part through the prostacyclin receptor. Blood Advances, 2017, 1, 1124-1131.	5.2	26
45	PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. PLoS ONE, 2021, 16, e0260124.	2.5	26
46	Biosynthesis of the Maresin Intermediate, 13S,14S-Epoxy-DHA, by Human 15-Lipoxygenase and 12-Lipoxygenase and Its Regulation through Negative Allosteric Modulators. Biochemistry, 2020, 59, 1832-1844.	2.5	25
47	Evaluation of receptorâ€ligand mechanisms of dualâ€targeted particles to an inflamed endothelium. Bioengineering and Translational Medicine, 2016, 1, 103-115.	7.1	23
48	DHA 12â€LOXâ€derived oxylipins regulate platelet activation and thrombus formation through a PKAâ€dependent signaling pathway. Journal of Thrombosis and Haemostasis, 2021, 19, 839-851.	3.8	23
49	5S,15S-Dihydroperoxyeicosatetraenoic Acid (5,15-diHpETE) as a Lipoxin Intermediate: Reactivity and Kinetics with Human Leukocyte 5-Lipoxygenase, Platelet 12-Lipoxygenase, and Reticulocyte 15-Lipoxygenase-1. Biochemistry, 2018, 57, 6726-6734.	2.5	22
50	Characterization of hemostasis in mice lacking the novel thrombosis susceptibility gene Slc44a2. Thrombosis Research, 2018, 171, 155-159.	1.7	20
51	In Vitro Biosynthetic Pathway Investigations of Neuroprotectin D1 (NPD1) and Protectin DX (PDX) by Human 12-Lipoxygenase, 15-Lipoxygenase-1, and 15-Lipoxygenase-2. Biochemistry, 2021, 60, 1741-1754.	2.5	20
52	In vivo modeling of docosahexaenoic acid and eicosapentaenoic acid-mediated inhibition of both platelet function and accumulation in arterial thrombi. Platelets, 2019, 30, 271-279.	2.3	17
53	Omega-6 DPA and its 12-lipoxygenaseâ€“oxidized lipids regulate platelet reactivity in a nongenomic PPARÎ±-dependent manner. Blood Advances, 2020, 4, 4522-4537.	5.2	17
54	Nfe2 is dispensable for early but required for adult thrombocyte formation and function in zebrafish. Blood Advances, 2018, 2, 3418-3427.	5.2	16

#	Article	IF	Citations
55	KLF11 (KrÃ¼ppel-Like Factor 11) Inhibits Arterial Thrombosis via Suppression of Tissue Factor in the Vascular Wall. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 402-412.	2.4	15
56	Modified two-step emulsion solvent evaporation technique for fabricating biodegradable rod-shaped particles in the submicron size range. Journal of Colloid and Interface Science, 2018, 518, 174-183.	9.4	14
57	Role of Human 15-Lipoxygenase-2 in the Biosynthesis of the Lipoxin Intermediate, 5S,15S-diHpETE, Implicated with the Altered Positional Specificity of Human 15-Lipoxygenase-1. Biochemistry, 2020, 59, 4118-4130.	2.5	14
58	A new way to treat proximal deep venous thrombosis using E-selectin inhibition. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2020, 8, 268-278.	1.6	14
59	Development of Poly Unsaturated Fatty Acid Derivatives of Aspirin for Inhibition of Platelet Function. Journal of Pharmacology and Experimental Therapeutics, 2016, 359, 134-141.	2.5	13
60	12-HETrE, An Endogenous Inhibitor of Platelet Activation,. Blood, 2011, 118, 3254-3254.	1.4	12
61	Synthetic high-density lipoproteins loaded with an antiplatelet drug for efficient inhibition of thrombosis in mice. Science Advances, 2020, 6, .	10.3	11
62	Antisense oligonucleotides and nucleic acids generate hypersensitive platelets. Thrombosis Research, 2021, 200, 64-71.	1.7	11
63	Identification of a Racially Dimorphic Variant in the Human Platelet PAR4 Thrombin Receptor Altering Platelet Function and Pharmacologic Inhibition. Blood, 2014, 124, 1434-1434.	1.4	11
64	Who is the real 12-HETrE?. Prostaglandins and Other Lipid Mediators, 2017, 132, 25-30.	1.9	9
65	Formation and Resolution of Pial Microvascular Thrombosis in a Mouse Model of Thrombotic Thrombocytopenic Purpura. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1817-1830.	2.4	9
66	Protease Activated Receptors Differentially Regulate Human Platelet Activation through Phosphatidic Acid-Dependent DAG Formation.. Blood, 2006, 108, 3906-3906.	1.4	7
67	Identification of the Genetic Mechanism Responsible for Racially-Dimorphic Expression of the Thrombin-Receptor Regulator, Pctp. Blood, 2015, 126, 415-415.	1.4	7
68	Defibrotide Therapy for SARS-CoV-2 ARDS. Chest, 2022, 162, 346-355.	0.8	7
69	Pharmacologic targeting of Cdc42 GTPase by a small molecule Cdc42 activity-specific inhibitor prevents platelet activation and thrombosis. Scientific Reports, 2021, 11, 13170.	3.3	6
70	Supplementation with omegaâ€3 or omegaâ€6 fatty acids attenuates platelet reactivity in postmenopausal women. Clinical and Translational Science, 2022, 15, 2378-2391.	3.1	6
71	We Can Do It Together: PAR1/PAR2 Heterodimer Signaling in VSMCs. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2775-2776.	2.4	5
72	Identification of a functional genetic variant driving racially dimorphic platelet gene expression of the thrombin receptor regulator, PCTP. Thrombosis and Haemostasis, 2017, 117, 962-970.	3.4	5

#	Article	IF	Citations
73	E-selectin inhibitor is superior to low-molecular-weight heparin for the treatment of experimental venous thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, 10, 211-220.	1.6	5
74	Dichotomous effects of exposure to bivalirudin in patients undergoing percutaneous coronary intervention on protease-activated receptor-mediated platelet activation. Journal of Thrombosis and Thrombolysis, 2013, 35, 209-222.	2.1	4
75	Racial Differences in Resistance to P2Y₁₂Receptor Antagonists in Type 2 Diabetic Subjects. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 33-43.	2.5	4
76	Resolvin the clot: DVT resolution through RvD4. Blood, 2019, 134, 1370-1371.	1.4	4
77	Coronary Heart Disease Risk Factors Take a Disproportional Toll on Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 750-751.	2.4	2
78	Dual antiplatelet therapy for PCI: Are we tailored to all?. Thrombosis Research, 2015, 135, 1045-1046.	1.7	2
79	Complement factors (H) into thrombosis. Blood, 2017, 129, 1065-1066.	1.4	2
80	Controlling the Clot: ANXA7 Regulates Collagen Activation of Platelet Through 12-LOX. Circulation Research, 2021, 129, 508-510.	4.5	2
81	New LINE(s) of Evidence for Genetic Regulation of Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 690-691.	2.4	1
82	Slounase, a Batroxobin Containing Activated Factor X Effectively Enhances Hemostatic Clot Formation and Reducing Bleeding in Hypocoagulant Conditions in Mice. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110185.	1.7	1
83	A Large Cluster of Micrornas At 14q32 Defines an RNA Expression Module That Accounts for Racial Differences in Protease Activated Receptor 4-Mediated Platelet Reactivity. Blood, 2012, 120, 380-380.	1.4	1
84	Novel 12-LOX Inhibitor ML355 Attenuates Platelet Reactivity and Impairs Thrombus Growth, Stability and Vessel Occlusion In Vivo. Blood, 2015, 126, 3442-3442.	1.4	1
85	Role of 12-LOX in the Platelet Storage Lesion. Blood, 2021, 138, 3241-3241.	1.4	1
86	Protein kinase CÎ± phosphorylates the TRPC1 channel and regulates store-operated Ca2+ entry in endothelial cells.. Journal of Biological Chemistry, 2011, 286, 36162.	3.4	0
87	Popping the lid on PAR4 activation. Blood, 2020, 136, 2101-2102.	1.4	0
88	PIâ€ƷK differentially regulates protease activated receptorâ€mediated platelet activation in humans through Rap1. FASEB Journal, 2007, 21, A603.	0.5	0
89	Irreversible Platelet Activation Requires PAR1 Regulation of Phosphatidylinositol Phosphates (PIPns) Activation of Rap1.. Blood, 2007, 110, 3889-3889.	1.4	0
90	PAR1â€mediated stable platelet aggregation requires temporal regulation of Rap1 activity by phosphatidylinositol phosphates (PIPns).. FASEB Journal, 2008, 22, 646.3.	0.5	0

#	Article	IF	Citations
91	12â€Lipoxygenase plays a significant role in regulation of human platelets activation. FASEB Journal, 2010, 24, 574.4.	0.5	0
92	Platelet 12-Lipoxygenase Is Required for Dense Granule Secretion and Platelet Aggregation: Role of 12-hLO In Platelet Hemostasis and Thrombosis. Blood, 2010, 116, 3203-3203.	1.4	0
93	Altered platelet reactivity in humans diagnosed with type 2 diabetes mellitus. FASEB Journal, 2011, 25, 1089.5.	0.5	0
94	Protein kinase C regulates agonistâ€mediated platelet activation downstream of 12â€lipoxygenase in human platelets. FASEB Journal, 2011, 25, 1089.1.	0.5	0
95	Differential signaling of PAR1 and PAR4 through 12â€hLO. FASEB Journal, 2011, 25, 1009.6.	0.5	0
96	The regulation of thrombosis and hemostasis by fatty acid metabolites. FASEB Journal, 2012, 26, 991.1.	0.5	0
97	An Ï‰-6 Fatty Acid, Dgla, Prevents Platelet Activation and Thrombosis in Vivo.. Blood, 2012, 120, 2169-2169.	1.4	0
98	Racial Differences In Thrombin-Induced Human Platelet PAR4 Reactivity. Blood, 2013, 122, 1054-1054.	1.4	0
99	Effect Of Age and Gender On Human Platelet mRNA and Micro-RNA Levels. Blood, 2013, 122, 3518-3518.	1.4	0
100	PAR4 Mediates an Elevated Risk for Thrombosis in Blacks Relative to Whites (LB602). FASEB Journal, 2014, 28, LB602.	0.5	0
101	12-HETrE, a Novel 12-LOX Oxylipin, Prevents Platelet Activation in a GÎ±s-like Manner. Blood, 2014, 124, 1436-1436.	1.4	0
102	Pharmacogenocis of PAR4: PAR4 Polymorphism Determines Platelet Response in the Presence of Dual Anti-Platelet Therapy. Blood, 2015, 126, 3446-3446.	1.4	0
103	The Common PAR4 Ala120Thr Variant Has a Major Effect on Platelet Reactivity to Thrombin and These Effects Are Enhanced with PAR1 and P2Y12 Inhibition. Blood, 2016, 128, 709-709.	1.4	0
104	Potent Anti-Platelet Metabolite, 12-HETrE, Inhibits Platelet Activation and Thrombosis In Vivo Via Activation of the IP Receptor. Blood, 2016, 128, 714-714.	1.4	0
105	The Antithrombotic Effects of 12â€LOX Derived Metabolites of DPA, Ï‰â€6. FASEB Journal, 2018, 32, 571.5.	0.5	0
106	Mitigation of SARS-CoV2-Mediated Endothelial Injury via Suppression of the Epigenetic Enzyme KMT2A/MLL1 in Macrophages. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, 10, 541-543.	1.6	0
107	207 Omega-3 and omega-6 fatty acids attenuate platelet reactivity in postmenopausal women. Journal of Clinical and Translational Science, 2022, 6, 31-32.	0.6	0